Evaxion A/S (NASDAQ:EVAX) Coverage Initiated by Analysts at Maxim Group

Research analysts at Maxim Group initiated coverage on shares of Evaxion A/S (NASDAQ:EVAX) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm set a “buy” rating and a $10.00 price target on the stock. Maxim Group’s price objective indicates a potential upside of 201.20% from the stock’s current price.

EVAX has been the topic of a number of other research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. JonesTrading raised shares of Evaxion A/S to a “strong-buy” rating in a research report on Wednesday, October 29th. Finally, Edward Jones initiated coverage on Evaxion A/S in a research report on Thursday, October 30th. They issued a “buy” rating and a $10.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $11.75.

Evaxion A/S Price Performance

NASDAQ EVAX opened at $3.32 on Thursday. The company has a 50 day simple moving average of $4.43 and a 200-day simple moving average of $4.58. Evaxion A/S has a 52-week low of $1.20 and a 52-week high of $12.15. The firm has a market capitalization of $27.69 million, a price-to-earnings ratio of -8.51 and a beta of 0.29.

Hedge Funds Weigh In On Evaxion A/S

Several large investors have recently made changes to their positions in the business. Northwestern Mutual Wealth Management Co. acquired a new stake in Evaxion A/S during the fourth quarter worth $38,000. Wesbanco Bank Inc. bought a new position in shares of Evaxion A/S during the 4th quarter worth about $48,000. Finally, SmartHarvest Portfolios LLC acquired a new stake in shares of Evaxion A/S during the 4th quarter valued at about $72,000. Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.